AB
ELVN icon

Amalgamated Bank’s Enliven Therapeutics ELVN Stock Holding History

Amalgamated Bank’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,237
Closed -$19K – 1994
2025
Q4 		$19K Buy
1,237
+19
+2% +$379 ﹤0.01% 2122
2025
Q3 		$25K Hold
1,218
– – ﹤0.01% 2032
2025
Q2 		$24K Hold
1,218
– – ﹤0.01% 2044
2025
Q1 		$24K Hold
1,218
– – ﹤0.01% 1996
2024
Q4 		$27K Hold
1,218
– – ﹤0.01% 2008
2024
Q3 		$31K Hold
1,218
– – ﹤0.01% 1983
2024
Q2 		$28K Buy
1,218
+431
+55% +$9.07K ﹤0.01% 2006
2024
Q1 		$14K Sell
787
-1,249
-61% -$19.2K ﹤0.01% 2284
2023
Q4 		$28K Sell
2,036
-234
-10% -$2.86K ﹤0.01% 2495
2023
Q3 		$31K Hold
2,270
– – ﹤0.01% 2453
2023
Q2 		$46K Buy
+2,270
New +$45.9K ﹤0.01% 2354

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amalgamated Bank's ELVN Position: Q1 2026 in Review

Amalgamated Bank sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 1,237 shares — an estimated $19K sold.

Amalgamated Bank first reported a position in ELVN in Q2 2023 and held it in 11 quarters. The position peaked at $46K in Q2 2023. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Amalgamated Bank reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,237 Enliven Therapeutics shares in Q1 2026, an estimated $19K.
  • Amalgamated Bank first reported a position in Enliven Therapeutics in Q2 2023 and held it in 11 quarters.
  • Amalgamated Bank's Enliven Therapeutics position peaked at $46K in Q2 2023.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.